Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (30086) 30086
Publication (2411) 2411
Book Review (447) 447
Book Chapter (364) 364
Book / eBook (359) 359
Newsletter (208) 208
Conference Proceeding (102) 102
Newspaper Article (91) 91
Dissertation (54) 54
Magazine Article (39) 39
Paper (21) 21
Transcript (20) 20
Trade Publication Article (14) 14
Government Document (4) 4
Data Set (2) 2
Presentation (1) 1
Reference (1) 1
Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18846) 18846
index medicus (12275) 12275
animals (7571) 7571
male (7398) 7398
female (7102) 7102
hematology (5609) 5609
risk factors (5012) 5012
peripheral vascular disease (4062) 4062
middle aged (3965) 3965
anticoagulants (3836) 3836
aged (3480) 3480
adult (3464) 3464
time factors (2985) 2985
factor xa inhibitors (2873) 2873
biochemistry & molecular biology (2841) 2841
thrombin (2826) 2826
anticoagulants - therapeutic use (2821) 2821
thrombosis (2717) 2717
analysis (2638) 2638
research (2343) 2343
factor xa (2262) 2262
coagulation (2110) 2110
venous thromboembolism (2047) 2047
tissue factor (1994) 1994
mice (1989) 1989
rivaroxaban (1964) 1964
heparin (1943) 1943
cardiac & cardiovascular systems (1924) 1924
pharmacology & pharmacy (1913) 1913
treatment outcome (1909) 1909
prevention (1869) 1869
anticoagulants - administration & dosage (1835) 1835
warfarin (1833) 1833
thromboembolism (1760) 1760
anticoagulants - adverse effects (1718) 1718
blood coagulation - drug effects (1688) 1688
proteins (1626) 1626
health aspects (1615) 1615
care and treatment (1605) 1605
kinetics (1553) 1553
atrial fibrillation (1543) 1543
blood coagulation (1539) 1539
administration, oral (1517) 1517
anticoagulants - pharmacology (1476) 1476
rats (1463) 1463
medicine & public health (1454) 1454
surgery (1447) 1447
factor xa - metabolism (1444) 1444
stroke (1439) 1439
molecular sequence data (1437) 1437
activation (1423) 1423
molecular-weight heparin (1407) 1407
expression (1397) 1397
aged, 80 and over (1360) 1360
amino acid sequence (1345) 1345
factor-xa (1335) 1335
dose-response relationship, drug (1291) 1291
cell biology (1278) 1278
protein binding (1276) 1276
dabigatran (1237) 1237
article (1229) 1229
hemorrhage - chemically induced (1209) 1209
adolescent (1208) 1208
thrombin - metabolism (1207) 1207
cancer (1191) 1191
blood-coagulation (1166) 1166
binding sites (1152) 1152
risk (1145) 1145
oncology (1127) 1127
deep-vein thrombosis (1107) 1107
medicine (1105) 1105
inflammation (1097) 1097
anticoagulation (1096) 1096
risk-factors (1075) 1075
research article (1073) 1073
factor xa inhibitor (1026) 1026
abridged index medicus (1014) 1014
drug therapy (1014) 1014
multidisciplinary sciences (1003) 1003
thromboplastin - metabolism (991) 991
mortality (976) 976
physiological aspects (976) 976
medicine, general & internal (955) 955
plasma (941) 941
atrial fibrillation - drug therapy (938) 938
therapy (936) 936
gene expression (927) 927
cells, cultured (917) 917
binding (912) 912
partial thromboplastin time (911) 911
heparin - pharmacology (909) 909
blood (907) 907
enoxaparin (906) 906
management (905) 905
pregnancy (895) 895
stroke - prevention & control (892) 892
apixaban (889) 889
retrospective studies (888) 888
venous thrombosis (861) 861
risk assessment (853) 853
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (137) 137
Robarts - Stacks (64) 64
UTL at Downsview - May be requested (64) 64
Engineering & Comp. Sci. - Stacks (47) 47
UofT at Mississauga - Stacks (47) 47
OISE - Stacks (28) 28
UofT at Scarborough - Stacks (21) 21
Collection Dvlpm't (Acquisitions) - Vendor file (15) 15
Collection Dvlpm't (Acquisitions) - Closed Orders (14) 14
Earth Sciences (Noranda) - Stacks (13) 13
Mathematical Sciences - Stacks (12) 12
Architecture Landscape (Shore + Moffat) - Stacks (6) 6
Online Resources - Online (6) 6
Indust. Rel's & Hum. Resources (Newman) - Library use only (5) 5
New College (Ivey) - Stacks (4) 4
St. Michael's College (John M. Kelly) - 2nd Floor (4) 4
Aerospace - Stacks (3) 3
Engineering & Comp. Sci. - May be requested in 6-10 wks (3) 3
Mathematical Sciences - Missing (3) 3
Trinity College (John W Graham) - Stacks (3) 3
Trinity College (John W Graham) - Storage (3) 3
UofT at Mississauga - Reference (3) 3
Victoria University E.J. Pratt - Stacks (3) 3
Astronomy & Astrophysics - Ask at library (2) 2
Criminology - Stacks (2) 2
Map & Data - Data Reference (2) 2
Physics - Stacks (2) 2
Providence Healthcare - Stacks (2) 2
Robarts - Reference (2) 2
Royal Ontario Museum - Stacks (2) 2
Trinity College (John W Graham) - Reference (2) 2
Victoria University E.J. Pratt - Reference (2) 2
Architecture Landscape (Shore + Moffat) - Protected Material (1) 1
Business (Joseph L Rotman) - Stacks (1) 1
Chemistry (A D Allen) - Stacks (1) 1
Credit Valley Hospital - Stacks (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Reference (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Institute for Christian Studies - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Map & Data - Data & GIS (1) 1
Map & Data - Map Collection (1) 1
New College (Ivey) - Reference (1) 1
OISE - Curriculum Resources (1) 1
OISE - Missing (1) 1
OISE - Reference (1) 1
OISE - Storage (1) 1
Robarts - Course Reserves (1) 1
Robarts - Protected Material (1) 1
Royal Ontario Museum - Reference Desk (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
UofT Schools - Reference (1) 1
UofT at Mississauga - May be requested in 6-10 wks (1) 1
UofT at Scarborough - Withdrawn (1) 1
West Park Healthcare Centre - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (30212) 30212
German (232) 232
French (190) 190
Spanish (122) 122
Japanese (103) 103
Russian (89) 89
Portuguese (38) 38
Polish (34) 34
Chinese (33) 33
Italian (27) 27
Czech (23) 23
Hungarian (13) 13
Swedish (9) 9
Korean (8) 8
Turkish (5) 5
Bulgarian (3) 3
Danish (3) 3
Norwegian (3) 3
Slovenian (3) 3
Arabic (2) 2
Slovak (2) 2
Bosnian (1) 1
Croatian (1) 1
Dutch (1) 1
Finnish (1) 1
Latin (1) 1
Lithuanian (1) 1
Ndonga (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study
by Agnelli, Giancarlo and Gallus, Alexander and Goldhaber, Samuel Z and Haas, Sylvia and Huisman, Menno V and Hull, Russel D and Kakkar, Ajay K and Misselwitz, Frank and Schellong, Sebastian and ODIXa-DVT Study Investigators
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 2, pp. 180 - 187
Background - An effective and safe oral anticoagulant that needs no monitoring for dose adjustment is urgently needed for the treatment of diseases that... 
Anticoagulants | Factor Xa | Deep-vein thrombosis | Thromboembolism | Thrombosis | CARDIAC & CARDIOVASCULAR SYSTEMS | thromboembolism | BAY-59-7939 | FONDAPARINUX | PREVENTION | PHASE-II EVALUATION | INITIAL TREATMENT | PHARMACODYNAMICS | HEPARIN | thrombosis | VENOUS THROMBOEMBOLISM | PHARMACOKINETICS | deep-vein thrombosis | anticoagulants | TOTAL HIP-REPLACEMENT | PERIPHERAL VASCULAR DISEASE | factor Xa | HEMATOLOGY | Thiophenes - therapeutic use | Factor Xa Inhibitors | Administration, Oral | Humans | Morpholines - administration & dosage | Thiophenes - toxicity | Anticoagulants - therapeutic use | Heparin - therapeutic use | Thiophenes - administration & dosage | Patient Selection | Pulmonary Embolism - diagnosis | Rivaroxaban | Adult | Morpholines - toxicity | Thrombosis - drug therapy | Safety | Morpholines - therapeutic use | Patient outcomes | Physiological aspects | Venous thrombosis | Anticoagulants (Medicine) | Dosage and administration | Blood coagulation factors | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
by Ruff, Christian T., MD and Giugliano, Robert P., MD, SM and Antman, Elliott M., MD and Crugnale, Sharon E., MS and Bocanegra, Tomas, MD and Mercuri, Michele, MD, PhD and Hanyok, James, PharmD and Patel, Indravadan, MD and Shi, Minggao, PhD and Salazar, Dan, PhD and McCabe, Carolyn H., BS and Braunwald, Eugene, MD
American Heart Journal, ISSN 0002-8703, 2010, Volume 160, Issue 4, pp. 635 - 641.e2
Background Vitamin K antagonists have been the standard oral antithrombotic used for more than a half century for prevention and treatment of thromboembolism.... 
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | PREVENT STROKE | PHARMACOKINETICS | THROMBIN | ANTITHROMBOTIC THERAPY | RISK | PREVALENCE | REGISTRY | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Thiazoles - therapeutic use | Atrial Fibrillation - physiopathology | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Thrombolytic Therapy - methods | Electrocardiography | Female | Myocardial Infarction - physiopathology | Retrospective Studies | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Myocardial Infarction - complications | Stroke - etiology | Myocardial Infarction - drug therapy | Aged | Warfarin | Care and treatment | Comparative analysis | Atrial fibrillation | Heart attack | Women | Anticoagulants | Cardiac arrhythmia | Hepatitis | Nonsteroidal anti-inflammatory drugs | Drug therapy | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor
by Becker, Richard C and Yang, Hongqiu and Barrett, Yuchen and Mohan, Puneet and Wang, Jessie and Wallentin, Lars and Alexander, John H and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala kliniska forskningscentrum (UCR)
Journal of Thrombosis and Thrombolysis, ISSN 0929-5305, 8/2011, Volume 32, Issue 2, pp. 183 - 187
An ability to readily determine an anticoagulant effect with an emerging class of direct, active site, oral factor Xa inhibitors is viewed by the medical... 
Medicine & Public Health | Hematology | Cardiology | Acute coronary syndrome | Ant-Xa activity | Apixaban | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Pyridones - pharmacokinetics | Humans | Middle Aged | Male | Factor Xa - metabolism | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Pyridones - administration & dosage | Pyrazoles - administration & dosage | Blood Coagulation Tests - methods | Female | Aged | Anticoagulants - pharmacokinetics | Pyrazoles - pharmacokinetics | Medical colleges | Safety regulations | Analysis | Cardiac patients | Liquid chromatography | Coronary heart disease | Mass spectrometry | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen
by Kubitza, Dagmar and Becka, Michael and Mueck, Wolfgang and Zuehlsdorf, Michael
British Journal of Clinical Pharmacology, ISSN 0306-5251, 04/2007, Volume 63, Issue 4, pp. 469 - 476
What is already known about this subject • Rivaroxaban is a novel anticoagulant with predictable, dose-proportional pharmacokinetics and pharmacodynamics in... 
rivaroxaban | BAY 59-7939 | NSAID | oral anticoagulant | Factor Xa inhibitor | BAY 59‐7939 | Rivaroxaban | Oral anticoagulant | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | REPLACEMENT | VENOUS THROMBOEMBOLISM | PHARMACOKINETICS | BLEEDING-TIME | PHARMACOLOGY & PHARMACY | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Administration, Oral | Anticoagulants - metabolism | Humans | Middle Aged | Morpholines - administration & dosage | Male | Morpholines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Anticoagulants - adverse effects | Naproxen - metabolism | Cross-Over Studies | Drug Interactions | Adolescent | Adult | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Morpholines - adverse effects | Anticoagulants (Medicine)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban an Oral, Direct Factor Xa Inhibitor in Patients Undergoing Major Orthopaedic Surgery
by Mueck, Wolfgang and Eriksson, Bengt I and Bauer, Kenneth A and Borris, Lars and Dahl, Ola E and Fisher, William D and Gent, Michael and Haas, Sylvia and Huisman, Menno V and Kakkar, Ajay K and Kalebo, Peter and Kwong, Louis M and Misselwitz, Frank and Turpie, Alexander G.G
Clinical Pharmacokinetics, ISSN 0312-5963, 2008, Volume 47, Issue 3, pp. 203 - 216
Background: There is a clinical need for novel oral anticoagulants with predictable pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor... 
Anticoagulants | Rivaroxaban | Pharmacodynamic modelling | Pharmacokinetic pharmacodynamic relationships | Factor IXA inhibitors | Pharmacokinetic modelling | Research and development | Orthopaedic surgery | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | BAY-59-7939 | VIVO COAGULATION TIME | VENOUS THROMBOEMBOLISM | DABIGATRAN ETEXILATE | HEALTHY-SUBJECTS | SAFETY | TOLERABILITY | PREVENTION | TOTAL HIP-REPLACEMENT | MODEL ANALYSIS | PHARMACOLOGY & PHARMACY | Age Factors | Factor Xa Inhibitors | Humans | Middle Aged | Prothrombin Time | Male | Thiophenes - administration & dosage | Dose-Response Relationship, Drug | Tissue Distribution | Venous Thromboembolism - prevention & control | Time Factors | Aged, 80 and over | Adult | Arthroplasty, Replacement, Knee | Female | Double-Blind Method | Morpholines - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Arthroplasty, Replacement, Hip | Thiophenes - pharmacokinetics | Models, Biological | Sex Factors | Aged | Morpholines - pharmacokinetics | Nonlinear Dynamics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939):  An Oral, Direct Factor Xa Inhibitor
by Roehrig, Susanne and Straub, Alexander and Pohlmann, Jens and Lampe, Thomas and Pernerstorfer, Josef and Schlemmer, Karl-Heinz and Reinemer, Peter and Perzborn, Elisabeth
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2005, Volume 48, Issue 19, pp. 5900 - 5908
Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme... 
DRUG DESIGN | CRYSTAL-STRUCTURES | POTENT | CHEMISTRY, MEDICINAL | COAGULATION-FACTOR XA | ANTICOAGULANTS | Factor Xa Inhibitors | Rats, Wistar | Stereoisomerism | Humans | Prothrombin Time | Half-Life | Biological Availability | Crystallography, X-Ray | Male | Structure-Activity Relationship | Anticoagulants - chemical synthesis | Rivaroxaban | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - chemical synthesis | Morpholines - chemical synthesis | Administration, Oral | Models, Molecular | Morpholines - pharmacology | Rats | Thiophenes - pharmacology | Fibrinolytic Agents - pharmacology | Thiophenes - chemical synthesis | Thiophenes - pharmacokinetics | Animals | Anticoagulants - pharmacology | Dogs | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | In Vitro Techniques
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
by M. M. Samama and J.-L. Martinoli and L. LeFlem and C. Guinet and G. Plu-Bureau and F. Depasse and E. Perzborn
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2010, Volume 103, Issue 4, pp. 815 - 825
Although there is no need for routine coagulation monitoring with rivaroxaban – an oral, direct factor Xa inhibitor – a haemostasis assay might be valuable to... 
fondaparinux | rivaroxaban | Clotting assays | venous thromboembolism | pharmacodynamics | Factor Xa inhibitor | New Technologies, Diagnostic Tools and Drugs | Rivaroxaban | Pharmacodynamics | Venous thromboembolism | Fondaparinux | DIRECT FXA-INHIBITORS | ANTICOAGULANTS | BAY-59-7939 | ANTITHROMBOTIC AGENT | TIME | IN-VITRO | THROMBIN GENERATION | PHARMACOKINETICS | PERIPHERAL VASCULAR DISEASE | factor Xa inhibitor | HEMATOLOGY | Predictive Value of Tests | Factor Xa Inhibitors | Humans | Prothrombin Time | Fibrinolytic Agents - blood | Thiophenes - administration & dosage | Blood Coagulation Tests - standards | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Dose-Response Relationship, Drug | Time Factors | Reproducibility of Results | Thrombelastography | Administration, Oral | Morpholines - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Calibration | Polysaccharides - pharmacology | Drug Monitoring - standards | Fibrinolytic Agents - pharmacology | Blood Coagulation - drug effects | Partial Thromboplastin Time | Fibrinolytic Agents - administration & dosage | Thrombin - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)
by Parsons‐Rich, D and Hua, F and Li, G and Kantaridis, C and Pittman, D. D and Arkin, S
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 05/2017, Volume 15, Issue 5, pp. 931 - 937
Essentials FXaI16L is a recombinant zymogen‐like variant of activated coagulation factor X (FXa). A phase 1 dose escalation clinical trial of FXaI16L was... 
clinical trial | hematologic agents | hemorrhagic disorders | blood coagulation factor | activated partial thromboplastin time | PF‐05230907 | PF-05230907 | HUMAN-PLASMA | ACTIVATION | PROTEIN | BYPASS | FACTOR-VIII | SPONTANEOUS INTRACEREBRAL HEMORRHAGE | THROMBIN GENERATION | INHIBITION | HEMOPHILIA-A | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Factor Xa - administration & dosage | Injections, Intravenous | Area Under Curve | Fibrin Fibrinogen Degradation Products - metabolism | Humans | Prothrombin Time | Half-Life | Male | Metabolic Clearance Rate | Recombinant Proteins | Healthy Volunteers | Young Adult | Peptide Hydrolases - blood | Antithrombin III | Coagulants - administration & dosage | Peptide Fragments - blood | Adult | Coagulants - pharmacokinetics | Factor Xa - adverse effects | Factor Xa - immunology | Double-Blind Method | Factor Xa - pharmacokinetics | Biomarkers - blood | Blood Coagulation - drug effects | Partial Thromboplastin Time | Adolescent | Prothrombin | Antibodies - blood | Coagulants - adverse effects | Coagulants - immunology | Coagulation factor X | Pharmacodynamics | Intravenous administration | Toxicity | Coagulation | Clinical trials | Thrombin | Antithrombin | Hemorrhage | Bleeding | Antibody response | Proenzymes | Thromboplastin | Coagulation factors | Immunogenicity | Plasma levels | Pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
by Siegal, Deborah M and Curnutte, John T and Connolly, Stuart J and Lu, Genmin and Conley, Pamela B and Wiens, Brian L and Mathur, Vandana S and Castillo, Janice and Bronson, Michele D and Leeds, Janet M and Mar, Florie A and Gold, Alex and Crowther, Mark A
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
The new oral anticoagulants have many advantages over warfarin, but one disadvantage is the inability to rapidly reverse their anticoagulant effects.... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | APIXABAN | WARFARIN | ATRIAL-FIBRILLATION | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Rivaroxaban - adverse effects | Female | Factor Xa - therapeutic use | Prothrombin - metabolism | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Antidotes - pharmacology | Peptide Fragments - metabolism | Double-Blind Method | Administration, Oral | Recombinant Proteins - pharmacology | Factor Xa - metabolism | Protein Precursors - metabolism | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Factor Xa - pharmacology | Factor Xa Inhibitors - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Antidotes - therapeutic use | Treatment outcome | Usage | Analysis | Clinical trials | Anticoagulants (Medicine) | Dosage and administration | Hemorrhage | Risk factors | Prevention | Anticoagulants | Side effects | Inhibitor drugs | Prothrombin | Thrombin | Thrombosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
by Patel, MR and ROCKET AF Study Investigators
American Heart Journal, ISSN 0002-8703, 2010, Volume 159, Issue 3, pp. 340 - 347.e1
Background Atrial fibrillation (AF), the most common significant cardiac arrhythmia, increases the risk of stroke, particularly in the elderly. Warfarin is... 
Cardiovascular | ENOXAPARIN | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | BAY 59-7939 | WARFARIN | ANTITHROMBOTIC THERAPY | PLACEBO-CONTROLLED TRIALS | DEEP-VEIN THROMBOSIS | ACTIVE-CONTROL TRIALS | THROMBOPROPHYLAXIS | ANTICOAGULATION | Factor Xa Inhibitors | Follow-Up Studies | Thiophenes - adverse effects | Humans | Warfarin - adverse effects | Secondary Prevention | Thiophenes - administration & dosage | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Rivaroxaban | Vitamin K - antagonists & inhibitors | Embolism - etiology | Morpholines - adverse effects | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Risk Factors | Medical Records | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Stroke - etiology | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Research Design | Prevention | Stroke (Disease) | Warfarin | Diet therapy | Atrial fibrillation | Clinical trials | Comparative analysis | Vitamins | Cardiac arrhythmia | Anticoagulants | Stroke | Aspirin | Embolisms | Patients | Studies | Hepatitis | Human immunodeficiency virus--HIV | Blood pressure | Clinical medicine | Drug therapy | Drug dosages | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
by Y. C. Barrett and Z. Wang and C. Frost and A. Shenker
Thrombosis and Haemostasis, ISSN 0340-6245, 12/2010, Volume 104, Issue 6, pp. 1263 - 1271
Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for prevention and treatment of thromboembolic diseases. Although routine... 
prothrombin time | anti-Xa activity | Factor Xa inhibitor | international normalised ratio | Apixaban | New Technologies, Diagnostic Tools and Drugs | Anti-Xa activity | International normalised ratio | Prothrombin time | ENOXAPARIN | THROMBOSIS | SAFETY | WARFARIN | PERIPHERAL VASCULAR DISEASE | factor Xa inhibitor | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | Predictive Value of Tests | Pyrazoles - therapeutic use | Reproducibility of Results | Factor Xa Inhibitors | Humans | Prothrombin Time | Anticoagulants - therapeutic use | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Pyridones - blood | Venous Thromboembolism - drug therapy | Anticoagulants - blood | Venous Thromboembolism - blood | Dose-Response Relationship, Drug | International Normalized Ratio | Rivaroxaban | Blood Coagulation - drug effects | Pyrazoles - blood | Blood Coagulation Tests | Isoxazoles - blood | Pyridones - therapeutic use | Clinical Trials, Phase II as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor
by PERZBORN, E and STRASSBURGER, J and WILMEN, A and POHLMANN, J and ROEHRIG, S and SCHLEMMER, K‐H and STRAUB, A
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 03/2005, Volume 3, Issue 3, pp. 514 - 521
BAY 59‐7939 is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention and treatment of arterial and venous thrombosis. BAY 59‐7939... 
antithrombotic activity | oral anticoagulant | Factor Xa inhibitor | Oral anticoagulant | Antithrombotic activity | RATS | ANTICOAGULANT | DX-9065A | EXPERIMENTAL THROMBOSIS | ARGATROBAN | ARTERIAL | POTENT | MODELS | PERIPHERAL VASCULAR DISEASE | factor Xa inhibitor | HEMATOLOGY | ACTIVE INHIBITOR | Rabbits | Factor Xa Inhibitors | Species Specificity | Venous Thrombosis - drug therapy | Humans | Morpholines - pharmacology | Rats | Dose-Response Relationship, Drug | Serine Proteinase Inhibitors - therapeutic use | Fibrinolytic Agents - pharmacology | Rivaroxaban | Animals | Thiophenes | Fibrinolytic Agents - therapeutic use | Blood Coagulation Tests | Inhibitory Concentration 50 | Venous Thrombosis - prevention & control | Thromboplastin - metabolism | Serine Proteinase Inhibitors - pharmacology | Disease Models, Animal
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights